 Genmab NASDAQ: GMAB and Seagen Inc NASDAQ: SGEN have jointly announced the submission of a marketing application with the FDA, seeking accelerated approval for tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The submission is based on the innovaTV 204 pivotal Phase 2 single-arm trial results evaluating tisotumab vedotin as monotherapy in this setting. 